bivalirudin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
hirudin derivatives 385 128270-60-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • bivalirudin
  • angiomax
  • angiox
  • hirulog
designed to bind to the alpha-thrombin catalytic site and anion-binding exosite for fibrin(ogen) recognition
  • Molecular weight: 2180.32
  • Formula: C98H138N24O33
  • CLOGP: 0
  • LIPINSKI: 3
  • HAC: 57
  • HDO: 28
  • TPSA: 901.57
  • ALOGS: -4.67
  • ROTB: 66

Drug dosage:

DoseUnitRoute
0.25 g P

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 0.27 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 8.10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 1 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.42 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 15, 2000 FDA MEDICINES CO

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coronary artery thrombosis 491.39 137.47 62 384 278 2357361
Thrombosis in device 272.33 137.47 40 406 613 2357026
Coagulation time abnormal 260.56 137.47 29 417 24 2357615
Device occlusion 225.06 137.47 35 411 794 2356845
Retroperitoneal haemorrhage 145.90 137.47 23 423 563 2357076

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coronary artery thrombosis 601.29 103.80 87 538 481 1745675
Thrombosis in device 445.96 103.80 72 553 879 1745277
Coagulation time abnormal 404.95 103.80 49 576 31 1746125
Thrombosis 216.59 103.80 56 569 7465 1738691
Procedural complication 172.32 103.80 33 592 1083 1745073
Device occlusion 153.13 103.80 29 596 893 1745263
Chest pain 143.33 103.80 51 574 19863 1726293
Hypotension 120.15 103.80 50 575 29604 1716552

Pharmacologic Action:

SourceCodeDescription
ATC B01AE06 BLOOD AND BLOOD FORMING ORGANS
ANTITHROMBOTIC AGENTS
ANTITHROMBOTIC AGENTS
Direct thrombin inhibitors
FDA EPC N0000175980 Anti-coagulant
FDA EPC N0000175518 Direct Thrombin Inhibitor
FDA MoA N0000009963 Thrombin Inhibitors
MeSH PA D000925 Anticoagulants
MeSH PA D000991 Antithrombins
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D006401 Hematologic Agents
MeSH PA D011480 Protease Inhibitors
MeSH PA D015842 Serine Proteinase Inhibitors
CHEBI has role CHEBI:50249 anticoagulant

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Percutaneous coronary intervention indication 415070008
Unstable Angina Pectoris during PTCA indication
Acute coronary syndrome off-label use 394659003
Intracranial hemorrhage contraindication 1386000
Bleeding contraindication 131148009

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.06 acidic
pKa2 3.51 acidic
pKa3 3.89 acidic
pKa4 4.04 acidic
pKa5 4.21 acidic
pKa6 4.49 acidic
pKa7 9.65 acidic
pKa8 11.93 acidic
pKa9 12.59 acidic
pKa10 12.84 acidic
pKa11 13.06 acidic
pKa12 13.08 acidic
pKa13 13.4 acidic
pKa14 13.64 acidic
pKa15 13.69 acidic
pKa16 13.81 acidic
pKa17 13.99 acidic
pKa18 10.75 Basic
pKa19 8.16 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Prothrombin Enzyme INHIBITOR Ki 8.60 IUPHAR CHEMBL

External reference:

IDSource
4021268 VUID
N0000148708 NUI
C0168273 UMLSCUI
D03136 KEGG_DRUG
400610005 SNOMEDCT_US
009031 NDDF
d04744 MMSL
15879 MMSL
60819 RXNORM
4021268 VANDF
129498009 SNOMEDCT_US
234768 MMSL
DB00006 DRUGBANK_ID
TN9BEX005G UNII
7282 INN_ID
CHEBI:59173 CHEBI
6470 IUPHAR_LIGAND_ID
CHEMBL2103749 ChEMBL_ID
CHEMBL3989957 ChEMBL_ID
16129704 PUBCHEM_CID
C074619 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Bivalirudin in 0.9% Sodium Chloride HUMAN PRESCRIPTION DRUG LABEL 1 0338-9572 INJECTION 250 mg INTRAVENOUS NDA 17 sections
Bivalirudin in 0.9% Sodium Chloride HUMAN PRESCRIPTION DRUG LABEL 1 0338-9576 INJECTION 500 mg INTRAVENOUS NDA 17 sections
Bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 0409-8300 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 17 sections
bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 0781-3158 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS NDA authorized generic 16 sections
Angiomax HUMAN PRESCRIPTION DRUG LABEL 1 0781-3447 INJECTION 250 mg INTRAVENOUS NDA 16 sections
bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 0781-9158 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS NDA authorized generic 16 sections
Bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 16729-275 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 16 sections
Bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 52958-034 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 16 sections
Bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 55111-652 INJECTION 250 mg INTRACAVERNOUS ANDA 16 sections
BIVALIRUDIN HUMAN PRESCRIPTION DRUG LABEL 1 55150-210 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 16 sections
Bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 60505-6101 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 16 sections
Bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 63323-562 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 18 sections
Angiomax HUMAN PRESCRIPTION DRUG LABEL 1 65293-001 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS NDA 16 sections
Bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 67457-256 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 16 sections
bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 69097-601 INJECTION 250 mg INTRAVENOUS ANDA 16 sections
bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 70511-141 INJECTION, SOLUTION 250 mg INTRAVENOUS NDA 16 sections
Bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 70860-402 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 16 sections
Bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 70860-403 INJECTION, SOLUTION 5 mg INTRAVENOUS NDA 16 sections